Finding Balance through Innovation

In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions. As Chief Operating Officer, he played an important role in the integration with Sanofi.

Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at Cleveland Clinic and an assistant professor of medicine at The Ohio State University. He has authored more than 40 articles and multiple book chapters.

Dr. Meeker is a Board member of BIO, the Biotechnology Industry Organization and the California Institute of Healthcare (CHI), an independent organization devoted to biomedical research and policy. He is also a board member of three non-profit organizations: Prize4Life, dedicated to accelerating the discovery of treatments for amyotrophic lateral sclerosis, BSCP, The Biomedical Science Careers Program, provides mentoring for academically outstanding students and PIC, The Boston Private Industry Council, a public-private partnership that connects business, the Boston Public Schools, higher education, and other stakeholders to create innovative workforce and education solutions.

Dr. Meeker received his MD from the University of Vermont Medical School. He completed an internal medicine residency at Beth Israel Hospital in Boston and a pulmonary/critical care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.